Grifols | GRFS - Sales Revenues


Grifols reported EUR2.18B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 190K 2.03M Sep/2025
Bio Path 0 0 Mar/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Capricor Therapeutics USD 0 11.13M Mar/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.18B 37.55M Sep/2025
Infinity Pharmaceuticals USD 583K 148K Jun/2023
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
TherapeuticsMD USD 234K 79K Jun/2024